Bio-Path (NASDAQ:BPTH) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note released on Thursday. The brokerage issued a sell rating on the stock.

Bio-Path Stock Performance

Shares of NASDAQ:BPTH opened at $1.14 on Thursday. Bio-Path has a 52-week low of $0.59 and a 52-week high of $12.00. The stock’s fifty day simple moving average is $0.89 and its 200-day simple moving average is $1.24.

Institutional Investors Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC bought a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 5.74% of the company’s stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.